The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...

Stocks rose sharply Monday after the U.S. and China said Monday they reached an agreement to temporarily slash most tariffs ...

Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation ...

The new research and development site will combine research, process development and clinical trial manufacturing ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).